Trial Profile
Single Center, Double Blind, Randomized, Crossover Study to Investigate the Impact of the Oral Contraceptive Yasmin (30 µg EE / 3 mg DRSP) Compared to Microgynon (30 µg / 150 LNG) on Hemostasis Parameters in 40 Female Volunteers.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Drospirenone/ethinylestradiol (Primary) ; Ethinylestradiol/levonorgestrel (Primary)
- Indications Pregnancy
- Focus Pharmacodynamics
- Sponsors Bayer
- 19 Dec 2008 New trial record.